Bimaxillary Orthognathic Surgery. 00
Conditions
Interventions
Intervention 1: Patients in the first group will be received "Magnesium Sulfate" an initial dose of 30 mg / kg body weight intravenously during 15 minutes and then continuously magnesium sulfate 10 mg
Treatment - Drugs
Patients in the first group will be received "Magnesium Sulfate" an initial dose of 30 mg / kg body weight intravenously during 15 minutes and then continuously magnesium sulfate 10 mg / kg / hr via p
Sponsors
Vice-Chancellery of Research and Technology, Shiraz University Of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to 40 Years
Inclusion criteria
Inclusion criteria: Patients with no history of systemic disease and without taking any analgesic medications criteria that were willing to cooperate in this study were enrolled; and Exclusion criteria included known allergy to the study drugs; hepatic and renal dysfunction ; patients with heart block or myocardial damage; morbid obesity (BMI = 35); neuromuscular disease; history of neuropathy; asthma; use of calcium channel blockers and Patients who did not sign the informed consent.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bleeding during surgery. Timepoint: During operation and postoperative. Method of measurement: CC. | — |
Secondary
| Measure | Time frame |
|---|---|
| Use of blood products. Timepoint: Postoperative. Method of measurement: CC.;Side effects of magnesium sulfate. Timepoint: Intraoperative. Method of measurement: Hemodynamic changes. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamid Reza Eftekharian
Shiraz University Of Medical
Outcome results
None listed